- 全部删除
- 您的购物车当前为空
LY3325656 is a GPR142 agonist suitable for clinical testing in human. LY3325656 demonstrated anti-diabetic benefits in pre-clinical studies and
ADME/PK properties suitable for human dosing. LY3325656 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes.
LY3325656 is a GPR142 agonist suitable for clinical testing in human. LY3325656 demonstrated anti-diabetic benefits in pre-clinical studies and
ADME/PK properties suitable for human dosing. LY3325656 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥ 16,100 | 10-14周 | |
50 mg | ¥ 21,300 | 10-14周 | |
100 mg | ¥ 27,500 | 10-14周 |
产品描述 | LY3325656 is a GPR142 agonist suitable for clinical testing in human. LY3325656 demonstrated anti-diabetic benefits in pre-clinical studies and ADME/PK properties suitable for human dosing. LY3325656 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes. |
分子量 | 448.44 |
分子式 | C21H23F3N6O2 |
CAS No. | 1998714-25-2 |
存储 | Shipping with blue ice. |
评论内容